FirstWord Group
banner
firstwordgroup.com
FirstWord Group
@firstwordgroup.com
210 followers 35 following 1.3K posts
FirstWord is a global leader in news and intelligence for the Pharma and MedTech industries. Find our services here www.firstwordpharma.com, www.firstwordhealthtech.com, and www.firstwordreports.com
Posts Media Videos Starter Packs
Sarepta's shares sink after antisense DMD therapies fail confirmatory trial $SRPT firstwordpharma.com/story/6515256
Neurocrine nabs ex-China rights to TransThera's NLRP3 portfolio $NBIX firstwordpharma.com/story/6515204
UCB gets nod for first therapy in ultra-rare mitochondrial disorder firstwordpharma.com/story/6515226
Lilly investing $3B in Netherlands plant that will produce orforglipron $LLY firstwordpharma.com/story/6515179
Pfizer escalates fight over Metsera with second lawsuit $PFE $NVO $MTSR firstwordpharma.com/story/6515178
Roche turns to Manifold and its AI platform for next-gen brain shuttles firstwordpharma.com/story/6514573
AAVantgarde draws $141M series B to advance pair of retinal gene therapies firstwordpharma.com/story/6514544
Roche's Gazyva maintains Phase III winning streak with SLE success firstwordpharma.com/story/6514532
FDA drug unit chief George Tidmarsh exits amid Aurinia spat firstwordpharma.com/story/6514557
Pfizer scores early FTC nod as Metsera tug-of-war with Novo turns legal $PFE $NVO $MTSR firstwordpharma.com/story/6513123
Otsuka nabs Asia-Pacific rights to 4DMT's retinal gene therapy for $85M $OTSKF $FDMT firstwordpharma.com/story/6512313
HRSA welcomes 9 drugs from the likes of J&J, BMS to 340B rebate pilot firstwordpharma.com/story/6512115
HIV, liver disease drugs boost Gilead's revenues as cell therapy slips $GILD firstwordpharma.com/story/6512095
AstraZeneca details late-stage win for next-gen C5 blocker in gMG $AZN firstwordpharma.com/story/6511991
Takeda's shares fall as it trims full-year guidance, pipeline $TAK firstwordpharma.com/story/6511695
FDA slaps holds on two Intellia studies following liver toxicity signal $NTLA firstwordpharma.com/story/6511140
Alnylam raises bar again as Amvuttra keeps beating expectations $ALNY firstwordpharma.com/story/6511138
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
Merck & Co., Eisai end liver cancer trial after OS miss $MRK $ESALF firstwordpharma.com/story/6510589
Samsung's health app will offer virtual doc visits via HealthTap integration firstwordhealthtech.com/story/6510393
Verily adds NVIDIA's AI tech to its data and analytics platform $NVDA firstwordhealthtech.com/story/6510309
Lilly, NVIDIA to build an AI supercomputer for drug discovery $LLY $NVDA firstwordpharma.com/story/6510379
FDA rebuff puts new dent in Regeneron's bid to crank up Eylea HD rollout $REGN firstwordpharma.com/story/6510409
BioMarin looks to shed Roctavian gene therapy after lackluster run $BMRN firstwordpharma.com/story/6510329
Mark Cuban deploys AI agents to support online pharmacy firstwordpharma.com/story/6510317